How many insider trades does FilingIQ track for XBIO?

FilingIQ tracks 38 Form 4 insider transactions for XBIO (Xenetic Biosciences, Inc.), covering filings from Dec 20, 2016 onwards. 1 of those were filed in the last 90 days.

Are XBIO insiders net buyers or net sellers?

Across the full Form 4 history for XBIO, 0 transactions (0%) were open-market purchases and 0 (0%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.

Where does XBIO insider data come from?

Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.

What sector is XBIO in?

Xenetic Biosciences, Inc. (XBIO) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $5.11M.

XBIO insider trading

NasdaqCM Healthcare

Xenetic Biosciences, Inc. — scored insider trade history from SEC Form 4 filings, parsed and contextualised by FilingIQ.

Total Form 4 trades

Last 90 days

Buys / sells

0% / 0%

Market cap

$5.11M

About Xenetic Biosciences, Inc.

Xenetic Biosciences, Inc., a biopharmaceutical company, focuses on advancing immune-oncology technologies to treat cancers. The company's proprietary DNase platform is designed to improve outcomes of existing treatments, including immunotherapies, by targeting neutrophil extracellular traps (NETs), which are involved in cancer progression, pancreatic ductal adenocarcinoma, colorectal carcinoma, and other gastrointestinal cancer. Its product pipeline includes XBIO-015 for treating pancreatic carcinoma and solid tumors; and XBIO-020 for treating solid tumors. The company also has partnered with biotechnology and pharmaceutical companies to develop its proprietary drug delivery platform, PolyXen, which as an enabling platform technology for protein and peptide drug delivery. It has collaboration agreements with Belgian Volition SARL Limited to develop NETs-targeted adoptive cell therapies for the treatment of cancer, as well as PJSC Pharmsynthez and Serum Institute of India to develop and launch ErepoXen for the treatment of anemia in chronic kidney disease patients; sublicensing agreement with Takeda Pharmaceutical Co. Ltd; exclusive sublicense agreement with CLS Therapeutics Ltd to develop DNase technology for the treatment of immunotherapies. The company offers under XDNASE, XCART, OncoHist, PolyXen, ErepoXen, and ImuXen trandemarks. Xenetic Biosciences, Inc. is headquartered in Framingham, Massachusetts.

Company website: www.xeneticbio.com

XBIO insider activity at a glance

FilingIQ has scored 38 insider transactions for XBIO since Dec 20, 2016. The most recent filing in our index is dated Apr 21, 2026.

Across the full history, 0 open-market purchases and 0 open-market sales were filed under transaction codes P and S respectively. Compensatory share awards (code A) and option exercises (code M) are tracked separately and not counted here.

View live XBIO trades on FilingIQ Raw filings on SEC EDGAR

Other Healthcare tickers with recent insider activity

UTHR 1,098

UNITED THERAPEUTICS Corp

APLS 279

Apellis Pharmaceuticals, Inc.

KMDA 218

KAMADA LTD

BMY 185

BRISTOL MYERS SQUIBB CO

ADPT 184

Adaptive Biotechnologies Corp

GH 169

Guardant Health, Inc.

ISRG 166

INTUITIVE SURGICAL INC

VTRS 165

Viatris Inc

Frequently asked

How many insider trades does FilingIQ track for XBIO?: FilingIQ tracks 38 Form 4 insider transactions for XBIO (Xenetic Biosciences, Inc.), covering filings from Dec 20, 2016 onwards. 1 of those were filed in the last 90 days.
Are XBIO insiders net buyers or net sellers?: Across the full Form 4 history for XBIO, 0 transactions (0%) were open-market purchases and 0 (0%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
Where does XBIO insider data come from?: Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.
What sector is XBIO in?: Xenetic Biosciences, Inc. (XBIO) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $5.11M.

Methodology & sources

Every XBIO insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). The FilingIQ composite score is documented in full on the team page and algo disclosure. Not investment advice; see disclaimer.